Revelation Biosciences, Inc. (REVBU) Stock Analysis
DELISTED 2023
What happened to Revelation Biosciences, Inc. (REVBU) stock?
Revelation Biosciences, Inc. (REVBU) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Revelation Biosciences, Inc. (REVBU) trades at $0.2897. Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immune system-based therapeutics and diagnostics. Sector: Healthcare.
Last analyzed: Jun 14, 2026Analyst Coverage for REVBU: REVBU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REVBU against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
REVBU: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Revelation Biosciences, Inc. (REVBU) Healthcare & Pipeline Overview
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in innovative immune system-focused therapeutics and diagnostics, with a pipeline targeting chronic nasal congestion, allergic rhinitis, and severe organ conditions, positioning itself strategically within the growing biotechnology sector.
What Is the Investment Thesis for REVBU?
Revelation Biosciences, Inc. presents a unique investment thesis driven by its innovative pipeline and strategic focus on immune system-related therapeutics and diagnostics. The company's lead product, REVTx-99b, is currently in a Phase Ib clinical trial, with potential market entry in the next 1-2 years if successful, addressing chronic nasal congestion and allergic rhinitis, which represent a significant market opportunity. Furthermore, the development of REVDx-501 could position the company favorably in the growing diagnostics market, especially in light of the ongoing demand for rapid testing solutions post-COVID-19. The company's reliance on clinical trial outcomes and regulatory approvals introduces inherent risks, but successful advancements could lead to substantial revenue growth. Investors should monitor the progress of clinical trials and any regulatory updates, as these factors will be critical in determining the company's future valuation and market position.
Based on FMP financials and quantitative analysis
REVBU Key Highlights
Clinical-stage with a diverse pipeline including REVTx-99b and REVDx-501.
- Focused on unmet medical needs in chronic nasal congestion and respiratory infections.
- Established in 2020, indicating a relatively young but innovative company.
- Headquartered in San Diego, a key biotechnology hub.
- No dividend yield currently, indicating reinvestment in growth.
Who Are REVBU's Competitors?
REVBU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| MRNA Moderna, Inc. | $139.86 | -19.80% | $55.5B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REVBU's Key Strengths?
Innovative pipeline with multiple therapeutic candidates.
- Focus on immune system-based therapies, a growing area in biotechnology.
- Experienced leadership team with a strong vision for growth.
What Are REVBU's Weaknesses?
Limited financial resources typical of clinical-stage companies.
- Dependence on successful clinical trial outcomes for product advancement.
- Relatively small employee base may limit operational capacity.
What Could Drive REVBU Stock Higher?
REVBU catalyst: Results from the Phase Ib clinical trial of REVTx-99b are expected in the next 12 months, which could significantly impact the company's valuation.
- Development of REVDx-501 is progressing, with potential for market introduction as demand for rapid diagnostics continues to rise.
- Strategic partnerships may be pursued to enhance the company's research and development capabilities.
What Are the Key Risks for REVBU?
Reliance on successful clinical trial outcomes poses a significant risk to the company's future.
- The competitive landscape in biotechnology is intense, with numerous companies vying for market share in similar therapeutic areas.
- Regulatory hurdles could delay the approval and commercialization of key products.
What Are the Growth Opportunities for REVBU?
- Growth opportunity 1: The global market for chronic rhinitis treatments is expected to reach $5 billion by 2028, driven by increasing prevalence and awareness. Revelation's REVTx-99b, currently in Phase Ib trials, could capture a significant share of this market if successful, providing a strong revenue stream upon commercialization.
- Growth opportunity 2: The diagnostics market, particularly for respiratory viral infections, is projected to grow at a CAGR of 11% through 2027. With the advancement of REVDx-501, Revelation Biosciences can leverage the ongoing demand for rapid testing solutions, positioning itself as a key player in this expanding sector.
- Growth opportunity 3: The increasing incidence of chronic kidney disease and NASH presents a substantial market opportunity, estimated to exceed $10 billion globally. Revelation's REVTx-300, targeting these severe organ conditions, could tap into this lucrative market, especially as awareness and treatment options expand.
- Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could enhance Revelation's research capabilities and market reach. Collaborations could provide access to additional resources, expertise, and distribution networks, accelerating the development and commercialization of its pipeline products.
- Growth opportunity 5: Expansion into international markets, particularly in Europe and Asia, could significantly enhance revenue potential. As healthcare systems globally seek innovative therapeutic solutions, Revelation's focus on immune system therapies positions it well to meet the demands of diverse healthcare markets.
What Threats Does REVBU Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles and the lengthy approval process for new therapies.
- Market volatility affecting funding and investment opportunities.
What Are REVBU's Competitive Advantages?
- Innovative pipeline targeting unmet medical needs in the healthcare sector.
- Focus on immune system therapies, providing a unique market positioning.
- Strong potential for patent protection on novel therapeutic candidates.
What Does REVBU Do?
Revelation Biosciences, Inc., founded in 2020 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to innovating immune system-focused therapeutics and diagnostics. The company's mission is to address unmet medical needs through its diverse pipeline of therapeutic candidates. Among its key products is REVTx-99b, which is currently in a Phase Ib clinical trial aimed at preventing or managing chronic nasal congestion and allergic rhinitis, two conditions that affect millions globally. In addition to REVTx-99b, the company is developing REVTx-200, an early-stage, nonclinical asset intended for intranasal administration, which could offer a new approach to treating respiratory conditions. Another significant candidate is REVTx-300, an investigational non-clinical stage compound designed to tackle severe organ conditions such as chronic kidney disease and non-alcoholic steatohepatitis (NASH). On the diagnostics front, Revelation Biosciences is advancing REVDx-501, a rapid, point-of-care in vitro diagnostic test engineered to swiftly identify various respiratory viral infections, including SARS-CoV-2, Influenza A and B, parainfluenza, and respiratory syncytial virus. This comprehensive approach positions Revelation Biosciences as a forward-thinking entity in the biotechnology industry, focusing on both therapeutic and diagnostic solutions to improve patient outcomes.
What Products and Services Does REVBU Offer?
- Develop immune system-focused therapeutics and diagnostics.
- Conduct clinical trials for innovative treatment options.
- Focus on unmet medical needs in respiratory and organ-related conditions.
- Advance rapid point-of-care diagnostic tests for viral infections.
- Engage in research and development to expand product pipeline.
How Does REVBU Make Money?
- Generate revenue through the commercialization of successful therapeutic and diagnostic products.
- Seek partnerships and collaborations to enhance research capabilities and market access.
- Leverage clinical trial outcomes to attract investment and funding for pipeline development.
What Industry Does REVBU Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, with a focus on addressing unmet medical needs through novel therapeutics and diagnostics. The global biotechnology market is projected to grow substantially, driven by advancements in genetic research, personalized medicine, and increasing demand for innovative treatment options. Revelation Biosciences, Inc. is positioned within this dynamic landscape, focusing on immune system therapies and diagnostics, areas that are gaining traction as healthcare providers seek more effective solutions for chronic and acute conditions. The competitive landscape includes various established players and emerging biopharmaceutical companies, making it essential for Revelation to differentiate its offerings through innovative products and clinical success.
Who Are REVBU's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from chronic nasal congestion, allergic rhinitis, and severe organ conditions.
- Laboratories and clinics requiring rapid diagnostic testing solutions.
Company Profile
Revelation Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO James M. Rolke. REVBU has traded publicly since 2020.
REVBU Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence, suggesting those closest to the company see potential upside.
- The community is buzzing about potential breakthroughs in their pipeline, creating positive momentum.
- Market perception seems to be shifting as investors recognize the value of their unique approach to infectious disease.
- There's a growing sense that the company is undervalued, with many believing the current price doesn't reflect their long-term potential.
Bear Case
- Negative community sentiment regarding recent clinical trial delays is creating uncertainty.
- Market perception is wary due to the company's history of volatile stock performance.
- Insider selling, although perhaps unrelated to company performance, is raising eyebrows within the community.
- Concerns linger about their ability to secure future funding, potentially hindering growth and expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
REVBU Latest News
No recent news available for REVBU.
Leadership: James M. Rolke
CEO
James M. Rolke has a robust background in the biotechnology sector, bringing extensive experience in leadership and strategic development. He has held various roles in biopharmaceutical companies, focusing on product development and clinical trials. Rolke's educational background includes a degree in life sciences, equipping him with the knowledge necessary to lead a clinical-stage company effectively.
Track Record: Under Rolke's leadership, Revelation Biosciences has successfully advanced its pipeline candidates into clinical trials, positioning the company for future growth and potential market entry. His strategic decisions have focused on expanding the company's research capabilities and fostering innovation.
Common Questions About REVBU (Healthcare)
What happened to Revelation Biosciences, Inc. (REVBU) stock?
Revelation Biosciences, Inc. (REVBU) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
Can I still buy REVBU shares?
No. REVBU stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for REVBU elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before REVBU stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Revelation Biosciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Revelation Biosciences, Inc. do?
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immune system-based therapeutics and diagnostics. The company has several candidates in its pipeline, including REVTx-99b for chronic nasal congestion and allergic rhinitis, and REVDx-501, a rapid diagnostic test for respiratory viral infections.
What are the main risks for REVBU?
Revelation Biosciences faces several risks, including reliance on successful clinical trial outcomes, which are critical for product advancement. Additionally, the competitive landscape in biotechnology is intense, and regulatory hurdles could delay the approval and commercialization of its key products, impacting future revenue.
How does Revelation Biosciences, Inc. manage patent expiration risks?
Revelation Biosciences, Inc. focuses on developing novel therapeutics and diagnostics that can be patented, thus protecting its intellectual property. The company also engages in lifecycle management strategies to extend the commercial viability of its products, ensuring continued revenue generation even as patents near expiration.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change as new developments occur.